Physician profile
Jonathan Schiff
NPI 1588694723
$7,092.95
in general payments reported to CMS, 2019-2025
37 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $603 · 2021: $1,337 · 2022: $1,224 · 2023: $1,060 · 2024: $1,121 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,652 · Education: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,651.51 |
| Education | $546.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,560.43 | 2019-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $1,124.06 | 2019-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $660.42 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $595.48 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $464.17 | 2023-2025 | Gemtesa |
| Urovant Sciences INC | $337.13 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $322.38 | 2020-2025 | Lynparza |
| Myovant Sciences INC. | $303.13 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $201.78 | 2021-2024 | Lynparza, Keytruda, Welireg |
| Ferring Pharmaceuticals INC. | $160.82 | 2019-2020 | |
| Neotract INC. | $141.45 | 2020 | |
| Progenics Pharmaceuticals, INC. | $133.12 | 2023-2025 | Pylarify |
| Zyla Life Sciences, INC. | $110.70 | 2020 | |
| Amgen INC. | $78.54 | 2021 | |
| Abbvie INC. | $76.82 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $71.26 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $68.31 | 2019-2020 | |
| Urogen Pharma, INC. | $68.24 | 2025 | |
| Antares Pharma, INC. | $64.55 | 2021-2022 | |
| Coloplast Corp | $58.75 | 2019-2025 | |
| Tolmar, INC. | $48.13 | 2023 | |
| Allergan, INC. | $46.91 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $44.80 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $38.93 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $37.92 | 2025 | Azmiro |
| Abc Home Medical Supply, INC. | $37.55 | 2025 | |
| Clarus Therapeutics INC. | $33.97 | 2021 | |
| Medtronic, INC. | $30.73 | 2025 | Interstim |
| Blue Earth Diagnostics | $25.79 | 2019 | |
| Endo Pharmaceuticals INC. | $24.76 | 2019 | |
| Tersera Therapeutics LLC | $21.68 | 2021 | |
| Halozyme INC | $20.53 | 2023 | |
| Therapeuticsmd, INC. | $17.90 | 2021 | |
| Immunitybio, INC. | $17.03 | 2025 | |
| Verity Pharmaceuticals INC. | $17.03 | 2025 | Trelstar |
| Boston Scientific Corporation | $14.52 | 2023 | Rezum Generator |
| Metuchen Pharmaceuticals | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Schiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.